Evaluation of the Clinical Effects of an Antiviral, Immunostimulant and Antioxidant Phytotherapy in Patients Suffering from COVID-19 Infection: An Observational Pilot Study
Ortore et al.
, Evaluation of the Clinical Effects of an Antiviral, Immunostimulant and Antioxidant Phytotherapy in Patients..
, International Journal of Translational Medicine, doi:10.3390/ijtm2020022
Retrospective case series of 240 patients in Italy in 2020, up to 96 years old, showing no mortality and 1.6% hospitalization with early treatment including vitamin C, quercetin, and green tea and red wine polyphenols.
The formulation was based on SARS-CoV-2 molecular docking studies. Low bioavailability is a known issue for polyphenols. Authors note that bioavailability may be improved with combinations of polyphenols which may have a synergistic effect, and via consumption with dietary fat.
Ortore et al., 16 Jun 2022, Italy, peer-reviewed, 12 authors, study period September 2020 - December 2021.
email@example.com (corresponding author), firstname.lastname@example.org, email@example.com, firstname.lastname@example.org, email@example.com, firstname.lastname@example.org, email@example.com, firstname.lastname@example.org, email@example.com, firstname.lastname@example.org, email@example.com, firstname.lastname@example.org.
Evaluation of the Clinical Effects of an Antiviral,
Immunostimulant and Antioxidant Phytotherapy in Patients
Suffering from COVID-19 Infection: An Observational
Massimiliano Ortore 1 , Elisa Grazioli 2,3 , Eliana Tranchita 2, *, Carlo Minganti 2 , Alessia Manteca 1 ,
Ludovico Tinto 1 , Claudia Cerulli 2 , Igino Fabi 1 , Antonella Foti 1 , Giovanna Borriello 1 , Paolo Riondino 1
and Attilio Parisi 2
Citation: Ortore, M.; Grazioli, E.;
Tranchita, E.; Minganti, C.; Manteca,
A.; Tinto, L.; Cerulli, C.; Fabi, I.; Foti,
A.; Borriello, G.; et al. Evaluation of
the Clinical Effects of an Antiviral,
Immunostimulant and Antioxidant
Phytotherapy in Patients Suffering
from COVID-19 Infection:
An Observational Pilot Study. Int. J.
Transl. Med. 2022, 2, 242–251.
Academic Editor: Bernhard Ryffel
Received: 5 May 2022
Accepted: 14 June 2022
Published: 16 June 2022
Publisher’s Note: MDPI stays neutral
Associazione Sinerfit, 00199 Rome, Italy; email@example.com (M.O.);
firstname.lastname@example.org (A.M.); email@example.com (L.T.); firstname.lastname@example.org (I.F.);
email@example.com (A.F.); firstname.lastname@example.org (G.B.); email@example.com (P.R.)
Department of Movement, Human and Health Sciences, University of Rome “Foro Italico”, 00135 Rome, Italy;
firstname.lastname@example.org (E.G.); email@example.com (C.M.); firstname.lastname@example.org (C.C.);
Department of Experimental and Clinical Medicine, “Magna Graecia” University, 88100 Catanzaro, Italy
Correspondence: email@example.com; Tel.: +39-0636733333
Abstract: Background: In the last two years, the COVID-19 pandemic has spread all over the world,
affecting millions of people. The same infection can manifest in different clinical conditions, ranging
from mild situations to severe patient impairment, up to their death. The COVID-19 infection can
activate innate and adaptive immune systems and cause massive inflammatory responses that is
important to treat as soon as possible. Methods: In the initial phase of the pandemic, a group of 240 unvaccinated subjects with COVID-19 disease was administered phytotherapy with immunostimulant
and antioxidant property to evaluate the role of this phytotherapeutic preparation in counteracting
the progression of the COVID-19 disease both in duration and complexity. Results: 161 patients were
treated with phytotherapy alone and the prevailing symptoms in the acute phase were rhinitis, fever,
cough, osteo-muscular pains; the other 79 patients were given a therapy with NSAIDs, symptomatic
drugs, monoclonal antibodies, corticosteroids, antibiotics, and/or heparin. The coexistence of comorbidity (such as diabetes, hypertension, gastro-intestinal disease) was recorded in 74 out of 240 subjects,
more frequently in the older subjects; there was no statistically significant correlation between the
presence of comorbidity and the duration of disease. Hospitalization rate in this population was
1.6% and lethality rate was 0%. Conclusion: The use of phytotherapy can represent a valid weapon
against COVID-19, since it showed no side effects and can also be used in association with other
pharmacological therapies to reduce the massive inflammatory responses of this infection.
Keywords: population health; infectious diseases; phytotherapy
with regard to jurisdictional claims in
published maps and institutional affiliations.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.